Gene therapy for RPE65-mediated inherited retinal dystrophy completes phase 3

The Lancet

Volumn 390, Issue 10097, 2017, Pages 823-824

  Lee, Helena ^a   Lotery, Andrew ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; BETA ACTIN; VORETIGENE NEPARVOVEC; CIS TRANS ISOMERASE;

CONTRAST SENSITIVITY; DRUG EFFICACY; DRUG SAFETY; ENHANCER REGION; HUMAN; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DYSTROPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VISUAL ACUITY; GENE THERAPY;

CIS-TRANS-ISOMERASES; GENETIC THERAPY; HUMANS; RETINAL DYSTROPHIES;

EID: 85023780018     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31622-7     Document Type: Note

References (12)

1. Russell, S, Bennett, J, Wellman, JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet, 2017 published online July 13. http://dx.doi.org/10.1016/S0140-6736(17)31868-8.
2. Hauswirth, WW, Aleman, TS, Kaushal, S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19 (2008), 979–990.
3. Carvalho, LS, Vandenberghe, LH, Promising and delivering gene therapies for vision loss. Vision Res 111 (2015), 124–133.
4. Maguire, AM, Simonelli, F, Pierce, EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358 (2008), 2240–2248.
5. Maguire, AM, High, KA, Auricchio, A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374 (2009), 1597–1605.
6. Bainbridge, JW, Smith, AJ, Barker, SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358 (2008), 2231–2239.
7. Cideciyan, AV, Jacobson, SG, Beltran, WA, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci USA 110 (2013), E517–E525.
8. Testa, F, Maguire, AM, Rossi, S, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2. Ophthalmology 120 (2013), 1283–1291.
9. Bennett, J, Wellman, J, Marshall, KA, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet 388 (2016), 661–672.
10. Jacobson, SG, Aleman, TS, Cideciyan, AV, et al. Human cone photoreceptor dependence on RPE65 isomerase. Proc Natl Acad Sci USA 104 (2007), 15123–15128.
11. Simonelli, F, Maguire, AM, Testa, F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 18 (2010), 643–650.
12. Prieto, L, Sacristan, JA, Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes, 1, 2003, 80.